Mother-to-child transmission of HIV is preventable, and we have a duty to ensure the burden of HIV is not handed down across generations.
image source: pexels
The DolPHIN 2 programme investigates the safe and effective use of dolutegravir for women who present with untreated HIV in late pregnancy
The team at the Infectious Diseases Institute, Kampala
DolPHIN 2 is a multinational project led by the University of Liverpool which aims to reduce the rate of mother to child transmission (MTCT) of HIV through research into a new HIV drug called dolutegravir.
RT @UNITAID: In sub-Saharan Africa, over 1 in 5 HIV-infected pregnant women are diagnosed in late pregnancy each year. @UoLDolphin2 investigates factors that influence late antenatal initiation and the adherence to and retention in combination antiretroviral therapy programmes in pregnancy. https://t.co/gds9CbxJGZ